| Literature DB >> 35654037 |
Nikhil Panicker1, Tae-In Kam2, Hu Wang3, Stewart Neifert4, Shih-Ching Chou5, Manoj Kumar1, Saurav Brahmachari1, Aanishaa Jhaldiyal6, Jared T Hinkle7, Fatih Akkentli4, Xiaobo Mao1, Enquan Xu1, Senthilkumar S Karuppagounder1, Eric T Hsu8, Sung-Ung Kang1, Olga Pletnikova9, Juan Troncoso10, Valina L Dawson11, Ted M Dawson12.
Abstract
Parkinson's disease (PD) is mediated, in part, by intraneuronal accumulation of α-synuclein aggregates andsubsequent death of dopamine (DA) neurons in the substantia nigra pars compacta (SNpc). Microglial hyperactivation of the NOD-like receptor protein 3 (NLRP3) inflammasome has been well-documented in various neurodegenerative diseases, including PD. We show here that loss of parkin activity in mouse and human DA neurons results in spontaneous neuronal NLRP3 inflammasome assembly, leading to DA neuron death. Parkin normally inhibits inflammasome priming by ubiquitinating and targeting NLRP3 for proteasomal degradation. Loss of parkin activity also contributes to the assembly of an active NLRP3 inflammasome complex via mitochondrial-derived reactive oxygen species (mitoROS) generation through the accumulation of another parkin ubiquitination substrate, ZNF746/PARIS. Inhibition of neuronal NLRP3 inflammasome assembly prevents degeneration of DA neurons in familial and sporadic PD models. Strategies aimed at limiting neuronal NLRP3 inflammasome activation hold promise as a disease-modifying therapy for PD.Entities:
Keywords: Caspase-1; NLRP3; PARIS; Parkinson’s disease; ZNF746; inflammasome; neurodegeneration; parkin; ubiquitination
Mesh:
Substances:
Year: 2022 PMID: 35654037 PMCID: PMC9357148 DOI: 10.1016/j.neuron.2022.05.009
Source DB: PubMed Journal: Neuron ISSN: 0896-6273 Impact factor: 18.688